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Abstract
© 2018  Leimuranta,  Khiroug  and  Giniatullin.  In  this  mini-review,  we  summarize  recent
discoveries and present new hypotheses on the role of cannabinoids in controlling trigeminal
nociceptive  system underlying  migraine  pain.  Individual  sections  of  this  review cover  key
aspects of this topic, such as: (i) the current knowledge on the endocannabinoid system (ECS)
with emphasis on expression of its components in migraine related structures; (ii) distinguishing
peripheral from central site of action of cannabinoids, (iii) proposed mechanisms of migraine
pain  and  control  of  nociceptive  traffic  by  cannabinoids  at  the  level  of  meninges  and  in
brainstem, (iv)  therapeutic  targeting in  migraine of  monoacylglycerol  lipase and fatty  acid
amide hydrolase,  enzymes which control  the level  of  endocannabinoids;  (v)  dual  (possibly
opposing) actions of cannabinoids via anti-nociceptive CB1 and CB2 and pro-nociceptive TRPV1
receptors.  We explore  the  cannabinoid-mediated  mechanisms in  the  frame of  the  Clinical
Endocannabinoid  Deficiency  (CECD)  hypothesis,  which  implies  reduced  tone  of
endocannabinoids in migraine patients. We further discuss the control of cortical excitability by
cannabinoids via inhibition of cortical spreading depression (CSD) underlying the migraine aura.
Finally,  we present our view on perspectives of Cannabis-derived (extracted or synthetized
marijuana components) or novel endocannabinoid therapeutics in migraine treatment.
http://dx.doi.org/10.3389/fphar.2018.00420
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